FMP
Novo Nordisk A/S
NVO
NYSE
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
87.37 USD
-1.34 (-1.53%)
Historical Prices
From:
To:
We are unable to load the chart at this time.
About
ceo
Mr. Lars Fruergaard Jorgensen
sector
Healthcare
industry
Biotechnology
website
https://www.novonordisk.comexchange
NYSE
Description
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for deliveri...
CIK
0000353278
ISIN
US6701002056
CUSIP
670100205
Address
Novo Allé 1
Phone
45 44 44 88 88
Country
DK
Employee
71,880
IPO Date
Apr 30, 1981
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
NVO Financial Summary
CIK
0000353278
Exchange
NYSE
Industry
Biotechnology
Sector
Healthcare
CUSIP
670100205
ISIN
US6701002056
Country
DK
Price
87.37
Beta
0.17
Volume Avg.
6.29M
Market Cap
358.71B
Shares
-
52-Week
81.5-148.15
DCF
133.09
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
29.62
P/B
-
Website
https://www.novonordisk.com
Upgrades and Downgrades
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest NVO News
It looks like there's no news available.
